Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Change in Dynamics? Suzuken Emerges as No. 2 among Big 4 Japan Wholesalers
November 15, 2023
- Kao, NANO MRNA to Initiate Joint Research for mRNA Drug Discovery
November 15, 2023
- iPark Institute Inks Collaboration Pact with South Korean Government
November 14, 2023
- Japan’s First Stelara Biosimilar to Skip November Listing on Risk of Import Delays: Fuji Pharma
November 14, 2023
- Taisho Hits “Reset” Button for Pharma Biz with 600-Plus Job Cuts
November 14, 2023
- Ajinomoto to Acquire US Gene Therapy CDMO for US$554 Million
November 14, 2023
- UCB Seeks Hidradenitis Suppurativa Nod for Bimzelx in Japan
November 13, 2023
- Otsuka Files NDA for Lupus Nephritis Drug in Japan
November 13, 2023
- Takeda Scores 1st US Nod for Ultra-Rare Blood Clotting Disorder
November 13, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- Takeda Gets US Clearance for Hutchmed’s Colorectal Cancer Drug
November 10, 2023
- Middle East Unrest Threatens Supply of Kaken’s Burn Eschar Remover
November 9, 2023
- Mitsubishi Licenses Neuropsychiatric Drug to Dutch Startup Kynexis
November 9, 2023
- Japan Ethical Drug Sales Up 6.8% in September: Crecon
November 9, 2023
- Japan OB/GYN Market Projected at 100 Billion Yen in FY2026: Fuji Keizai
November 9, 2023
- CSL Launches Original Home Delivery Service for Hizentra
November 8, 2023
- Upsher-Smith’s Livalo Generic Hits US Market: Sawai
November 8, 2023
- Eisai CEO Confident of Achieving Leqembi Sales Goal of 10 Billion Yen in FY2023
November 8, 2023
- Keytruda Snares Title in Japan Sales Ranking in October: Encise
November 8, 2023
- 180 Employees Apply for Santen’s Voluntary Buyout Program
November 8, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…